Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Found 3599 publications
Subcutaneous Drug Delivery Market & Pipeline Insight US$ 2,400.00

... life threatening effects. Also, every year large number of protein based drugs are introduced in market for the treatment of various ailments. ... innovative products with higher therapeutic capabilities will enter in market in coming years. “Subcutaneous Drug Delivery Market & Pipeline Insight” Report Findings ...

Jan, 2015 1800 pages
Global Orphan Drugs Industry 2014 Market Research Report US$ 2,850.00

2014 Global Orphan Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Orphan ... , Germany, Japan and China). The report firstly introduced the Orphan Drugs basics: definitions, classifications, applications and industry chain overview; ...

Jan, 2015 176 pages
2015 Global Therapeutic Drug Monitoring Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment US$ 7,500.00

... a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."Therapeutic Dry Monitoring: US, Europe, Japan" is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants ...

Jan, 2015 306 pages
2015 Global Nucleic Acid Testing and DNA Sequencing Market: Facilities, Test Volumes, and Sales Forecasts by Country (DataPack) US$ 1,500.00

This report provides: Estimates of facilities performing DNA sequencing and molecular diagnostic testing in France, Germany, Italy, Japan, Spain, UK and USA. Five-year test volume and sales forecasts by country.

Jan, 2015
2015 Global Nucleic Acid Testing (NAT) Market: Sales Forecasts by Country and Strategic Profiles of Leading Suppliers US$ 3,500.00

... , as well as test volume and sales forecasts by country. The report also presents strategic profiles of current and emerging suppliers of nucleic acid testing products in terms of their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and ...

Jan, 2015 109 pages
2015 Global Drugs of Abuse Testing Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment US$ 7,500.00

... for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."Drugs of Abuse Testing Market: US, Europe, Japan" is a unique study designed to help current suppliers and potential market entrants identify and evaluate emerging ...

Jan, 2015 311 pages
2015 Analysis of Nucleic Acid Testing Instrumentation, and Strategic Profiles of Leading Suppliers US$ 3,500.00

... is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman ...

Jan, 2015 103 pages
2015 Analysis of Nucleic Acid Diagnostic Technologies, and Strategic Profiles of Leading Suppliers US$ 3,500.00

... , biochips, genosensors, microarrays, labs-on-the-chip, and other.The report also presents strategic assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative ...

Jan, 2015 180 pages
2015 Analysis of Emerging Nucleic Acid Testing Assays, and Strategic Profiles of Leading Suppliers US$ 3,500.00

... clinical significance and market needs for major current and emerging NAT assays, as well as extensive listings of companies developing and marketing ... . This report also presents strategic assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios ...

Jan, 2015 549 pages
Intramuscular Drug Delivery Market & Pipeline Insight US$ 2,400.00

... The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used ... supposed to be cost effective along with pharmacologically efficient and minimized side effects. “Intramuscular Drug Delivery Market & Pipeline Insight” Report Findings: ...

Jan, 2015 900 pages
Small Molecule Cancer Drug Clinical Pipeline Insight US$ 2,400.00

... the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers. Development of small molecule cancer drug generally ... Insight” Report Findings: Role of Small Molecule Drug in Cancer Treatment Mechanism of Small Molecule Cancer Drug Small Molecule Cancer Drugs Market Dynamics ...

Jan, 2015 1650 pages
Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure US$ 3,000.00

... Medicine and Stem cell based Cell therapies- Drugs of the Future Offering Hope for Cure'. This report describes the key ... Inc. 2. OCATA Therapeutics Inc. 3. Orgenesis 4. TiGenix NV 5. Pluristem Therapeutics Inc 6. Mesoblast Ltd 7. Medipost Co. Ltd 8. JCR Pharmaceuticals 9. Japan Tissue Engineering Co., Ltd

Jan, 2015 50 pages
Zanamivir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Zanamivir indications: Treatment or prophylaxis of infections due to Influenza A or B viruses innovator: Glaxosmithkline (Relenza) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Vorapaxar - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Vorapaxar indications: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease innovator: Merck (Zontivity) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Voglibose - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly ... Name: Voglibose indications: Lowering post-prandial blood glucose levels in people with diabetes mellitus innovator: Mascot Health (Voglib) Country Coverage ...

Jan, 2015
Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... : Vilanterol indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease, in combination with Umeclidinium bromide; Treatment of asthma in combination with Fluticasone furoate; Maintenance treatment of airflow obstruction and for reducing exacerbations in ...

Jan, 2015
Vemurafenib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Vemurafenib indications: Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma innovator: Roche (Zelboraf) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Umeclidinium bromide, Vilanterol - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Umeclidinium bromide, Vilanterol indications: Maintenance bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease innovator: GlaxoSmithKline (Anoro Ellipta, Laventair) Country Coverage: Australia Canada France ...

Jan, 2015
Umeclidinium bromide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Umeclidinium bromide indications: Maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease innovator: GlaxoSmithKline (Incruse, Incruse Ellipta) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Tofacitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tofacitinib indications: Treatment of psoriasis; Treatment of rheumatoid arthritis optionally in combination with Methotrexate innovator: Pfizer (Xeljanz) Country Coverage: Australia Canada France Germany Great Britain Italy ...

Jan, 2015
Telithromycin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... spectrum of Telithromycin; Treatment of acute exacerbation of chronic bronchitis; Treatment of acute sinusitis; Treatment of tonsillitis or pharyngitis caused by streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of ...

Jan, 2015
Telaprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Telaprevir indications: Treatment of chronic hepatitis C genotype 1 infection in combination with Peginterferon alfa and Ribavirin innovator: Vertex Pharm (Incivek); Janssen (Incivo) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Teduglutide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Add your own notes, save searches and results This report covers: International Nonproprietary Name: Teduglutide indications: Treatment of short bowel syndrome innovator: NPS Pharma (Revestive, Gattex) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Tedizolid - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... Nonproprietary Name: Tedizolid indications: Treatment of acute bacterial skin and skin structure infections innovator: Cubist Pharm (Sivextro) Country Coverage: Australia ...

Jan, 2015
Tasimelteon - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... own notes, save searches and results This report covers: International Nonproprietary Name: Tasimelteon indications: Treatment of non-24-hour sleep-wake disorder innovator: Vanda Pharm (Hetlioz) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA Please ...

Jan, 2015
Tafluprost - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tafluprost indications: Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension, optionally as adjunctive therapy to beta blockers innovator: Santen (Taflotan, Tapros); Merck (Saflutan, Zioptan) ...

Jan, 2015
Ruxolitinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Ruxolitinib indications: Treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF innovator: Incyte (Jakafi); Novartis (Jakavi) Country Coverage: ...

Jan, 2015
Rufinamide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Rufinamide indications: Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome innovator: Eisai (Banzel, Inovelon) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Roflumilast - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Roflumilast indications: Treatment and maintenance of severe chronic obstructive pulmonary disease, optionally in combination with bronchodilators and/or corticosteroids innovator: Nycomed (Daxas, Libertek); Merck (Daxas); Forest Res ( ...

Jan, 2015
Rilpivirine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Rilpivirine indications: Treatment of HIV-1 in combination with Ritonavir and other antiretroviral agents innovator: Tibotec (Edurant); Gilead (Eviplera); Janssen (Edurant) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Retigabine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Retigabine indications: Adjunctive treatment of partial onset seizures innovator: Glaxosmithkline (Trobalt); Valeant (Potiga) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain ...

Jan, 2015
Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source ... Name: Repaglinide indications: Treatment of type 2 diabetes mellitus innovator: Novo Nordisk (Prandin, NovoNorm, GlucoNorm, Prandimet); Daiichi Sankyo (Prandin) Country Coverage ...

Jan, 2015
Ranelic acid - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... : International Nonproprietary Name: Ranelic acid indications: Treatment of postmenopausal osteoporosis to reduce the risk of fractures, optionally in combination with Vitamin D and/or Calcium innovator: Servier (Protos, Osseor, Protelos) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Quetiapine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Nonproprietary Name: Quetiapine indications: Treatment of schizophrenia; Treatment of depressive episodes associated with bipolar disorder; Treatment or prevention of relapse/recurrence of manic, depressive or mixed episodes of bipolar disorder or of acute mania associated with bipolar disorder, as ...

Jan, 2015
Ponatinib - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of patent ... or blast phase chronic myeloid leukaemia or Philadelphia chromosome positive acute lymphoblastic leukaemia in patients with T315I mutation or no other tyrosine kinase therapy ...

Jan, 2015
Ospemifene - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... your own notes, save searches and results This report covers: International Nonproprietary Name: Ospemifene indications: Treatment of moderate to severe dyspareunia innovator: Shionogi (Osphena) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA Please ...

Jan, 2015
Ocriplasmin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... , save searches and results This report covers: International Nonproprietary Name: Ocriplasmin indications: Treatment of symptomatic vitreomacular adhesion innovator: ThromboGenics (Ocriplasmin); Alcon (Ocriplasmin) Country Coverage: Australia Canada France Germany Great Britain Italy Japan ...

Jan, 2015
Nelarabine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... notes, save searches and results This report covers: International Nonproprietary Name: Nelarabine indications: Treatment of acute lymphoblastic leukaemia innovator: GlaxoSmithKline (Arranon, Atriance) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Metformin, Vildagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Metformin, Vildagliptin indications: Treatment of type 2 diabetes mellitus, optionally in combination with a sulphonylurea or Insulin innovator: Novartis (Galvumet, Sobrea, Eucreas, Icandra, Zomarist) Country Coverage: Australia Canada France ...

Jan, 2015
Metformin, Sitagliptin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Metformin, Sitagliptin indications: Improvement of glycemic control in patients with type 2 diabetes mellitus, optionally in combination with a PPARy agonist innovator: Merck (Janumet, Velmetia, Efficib, Ristfor) Country Coverage: ...

Jan, 2015
Metformin, Repaglinide - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of patent ... : Metformin, Repaglinide indications: Adjunctive treatment to diet and exercise for improving glycaemic control in patients with type 2 diabetes mellitus innovator: Novo ...

Jan, 2015
Metformin, Dapagliflozin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know. “The most extensive source of ... : Metformin, Dapagliflozin indications: Adjunctive treatment to diet and exercise for improving glycaemic control innovator: AstraZeneca (Xigduo); Bristol Myers Squibb (Xigduo) ...

Jan, 2015
Metformin, Canagliflozin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Metformin, Canagliflozin indications: Adjunctive therapy to diet and exercise to improve glycaemic control in patients with type 2 diabetes innovator: Janssen (Invokamet, Vokanamet) Country Coverage: Australia Canada France Germany ...

Jan, 2015
Meropenem - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Meropenem indications: Treatment of hospital acquired lower respiratory tract infection; Treatment of nosocomial pneumonia; Treatment of complicated urinary tract infection; Treatment of complicated skin and skin structure infections; Treatment of ...

Jan, 2015
Memantine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... own notes, save searches and results This report covers: International Nonproprietary Name: Memantine indications: Treatment of Alzheimer's disease innovator: Forest Labs (Namenda); Lundbeck (Ebixa) Country Coverage: Australia Canada France Germany Great Britain Italy Japan Spain USA ...

Jan, 2015
Maraviroc - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... save searches and results This report covers: International Nonproprietary Name: Maraviroc indications: Treatment of CCR5-tropic HIV in combination with other antiretroviral agents innovator: Pfizer (Celsentri, Selzentry) Country Coverage: Australia Canada France Germany Great Britain Italy ...

Jan, 2015
Macitentan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... This report covers: International Nonproprietary Name: Macitentan indications: Treatment of pulmonary arterial hypertension, optionally in combination with approved PAH treatments, including phosphodiesterase-5 inhibitors or inhaled prostanoids innovator: Actelion (Opsumit) Country Coverage: Australia ...

Jan, 2015
Lercanidipine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Lercanidipine indications: Treatment of hypertension, optionally in combination with Felodipine or thiazide diuretics innovator: Napp (Zanidip); Solvay (Zanidip, Zan-Extra); Recordati (Zanidip) Country Coverage: Australia Canada ...

Jan, 2015
Ketorolac, Phenylephrine - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Ketorolac, Phenylephrine indications: Maintenance of pupil size by preventing intraoperative miosis and reducing postoperative ocular pain innovator: Omeros (Omidria) Country Coverage: Australia Canada France Germany Great ...

Jan, 2015
Ivacaftor - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Ivacaftor indications: Treatment of cystic fibrosis in patients having a G551D mutation in the cystic fibrosis transmembrane conductance regulator gene innovator: Vertex (Kalydeco) Country Coverage: Australia Canada France Germany ...

Jan, 2015
1 2 3 4 5 >
Skip to top